-+ 0.00%
-+ 0.00%
-+ 0.00%

Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients

Benzinga·11/18/2026 12:36:03
Diffusion vocale

Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today presented new preclinical data demonstrating the potential of atebimetinib to serve as a backbone for combinations with multiple classes of anticancer agents. The findings, generated using both animal models and three-dimensional (3D) tumor models of pancreatic ductal adenocarcinoma (PDAC), identify multiple synergistic combination strategies and provide further support for atebimetinib’s potential to play a central role as a MAPK pathway backbone for combinations in pancreatic cancer and beyond. The data will be presented in a Poster Spotlight presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

The research being presented today includes results from Immuneering’s humanized 3D tumor growth assay (3D-TGA) platform, which previously identified the potential for atebimetinib to enhance the activity of gemcitabine and nab-paclitaxel (GnP), a combination subsequently supported by encouraging clinical results in the Company’s Phase 2a study in first-line pancreatic cancer. This combination is now being evaluated in MAPKeeper 301, a phase 3 pivotal trial evaluating atebimetinib plus mGnP versus GnP.

Key findings include:

Broad synergy with targeted therapies: Atebimetinib demonstrated synergistic activity in preclinical PDAC models when combined with multiple mutation-specific KRAS inhibitors targeting KRAS G12C, G12D, and G12V, PRMT5 inhibitors, as well as agents targeting BRAF, EGFR, and other components of the MAPK signaling pathway.
In vivo validation of KRAS inhibitor combinations: Combination activity with a KRAS G12D-targeted agent was confirmed in an in vivo pancreatic cancer xenograft model, providing additional evidence of atebimetinib’s potential to enhance the activity of mutant-selective RAS-targeted therapies.
Activity with complementary cancer treatment mechanisms: Atebimetinib demonstrated promising combination activity with agents targeting pathways involved in cancer cell survival, proliferation, and resistance, including GSK-3β, PI3K/mTOR, CDK4/6, and other targets, as well as multiple chemotherapy agents.
Biomarker-driven treatment opportunities: Combination activity was particularly pronounced in models with specific genomic characteristics, including matching KRAS mutations for vertical pathway inhibition and MTAP deletion for combinations involving PRMT5 inhibitors. These findings support the potential for atebimetinib to serve as a broad, all-comers MAPK backbone combined with specific agents targeted at particular patient populations.
Potential utility across multiple lines of therapy: The results support a proposed treatment strategy in which atebimetinib could be deployed in combination with chemotherapy in the first-line setting, potentially combined with mutant-selective RAS inhibitors in subsequent treatment, and paired with biomarker-selected therapies following RAS inhibitor exposure.

 

Presentation Details:

Title: Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma.

Abstract Number: 22

Poster Number: PB-003

Presenter: Anna Travesa

Date: Thursday, November 19, 2026